Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

December 15, 2023

https://www.prnewswire.com/news-releases/aadi-bioscience-reports-interim-results-from-precision1-trial-of-nab-sirolimus-demonstrating-anti-tumor-activity-in-solid-tumors-with-tsc1-or-tsc2-inactivating-alterations-302016094.html

Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically...
https://www.prnewswire.com/news-releases/aadi-bioscience-reports-interim-results-from-precision1-trial-of-nab-sirolimus-demonstrating-anti-tumor-activity-in-solid-tumors-with-tsc1-or-tsc2-inactivating-alterations-302016094.html

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.